Evans M D, Hollon S D, DeRubeis R J, Piasecki J M, Grove W M, Garvey M J, Tuason V B
Department of Psychology, University of Minnesota, Minneapolis.
Arch Gen Psychiatry. 1992 Oct;49(10):802-8. doi: 10.1001/archpsyc.1992.01820100046009.
Patients successfully treated during a 3-month period with either imipramine hydrochloride pharmacotherapy, cognitive therapy, or combined cognitive-pharmacotherapy were monitored during a 2-year posttreatment follow-up period. Half of the patients treated with pharmacotherapy alone continued to receive study medications for the first year of the follow-up. All other patients discontinued treatment at the end of the acute treatment phase. Patients treated with cognitive therapy (either alone or in combination with medication) evidenced less than half the rate of relapse shown by patients in the medication--no continuation condition, and their rate did not differ from that of patients provided with continuation medication. It appears that providing cognitive therapy during acute treatment prevents relapse. Whether this preventive effect extends to recurrence remains to be determined.
在为期3个月的时间里，使用盐酸丙咪嗪药物治疗、认知疗法或认知 - 药物联合疗法成功治疗的患者，在治疗后的2年随访期内接受监测。仅接受药物治疗的患者中有一半在随访的第一年继续接受研究药物治疗。所有其他患者在急性治疗阶段结束时停止治疗。接受认知疗法（单独或与药物联合）治疗的患者复发率不到未继续用药的药物治疗患者的一半，且其复发率与接受继续用药的患者无异。看来在急性治疗期间提供认知疗法可预防复发。这种预防效果是否能延伸至复发仍有待确定。
